دورية أكاديمية
Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations.
| العنوان: | Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. |
|---|---|
| المؤلفون: | Winklhofer-Roob BM; Division of Gastroenterology and Nutrition, Department of Pediatrics, University of Zurich, Switzerland., van't Hof MA, Shmerling DH |
| المصدر: | The American journal of clinical nutrition [Am J Clin Nutr] 1996 May; Vol. 63 (5), pp. 722-8. |
| نوع المنشور: | Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 0376027 Publication Model: Print Cited Medium: Print ISSN: 0002-9165 (Print) Linking ISSN: 00029165 NLM ISO Abbreviation: Am J Clin Nutr Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : [New York, NY] : Elsevier Original Publication: Bethesda, MD : American Society of Clinical Nutrition |
| مواضيع طبية MeSH: | alpha-Tocopherol*/*analogs & derivatives, Antioxidants/*pharmacokinetics , Cystic Fibrosis/*blood , Vitamin E/*analogs & derivatives , Vitamin E/*blood , Vitamin E/*pharmacokinetics , Vitamin E Deficiency/*prevention & control, Administration, Oral ; Adolescent ; Adult ; Antioxidants/administration & dosage ; Antioxidants/therapeutic use ; Child ; Child, Preschool ; Cholesterol/blood ; Cystic Fibrosis/complications ; Cystic Fibrosis/metabolism ; Dose-Response Relationship, Drug ; Female ; Humans ; Infant ; Liver Diseases/complications ; Liver Diseases/metabolism ; Male ; Time Factors ; Tocopherols ; Vitamin E/administration & dosage ; Vitamin E/therapeutic use ; Vitamin E Deficiency/etiology |
| مستخلص: | To investigate the efficacy of three different vitamin E preparations for optimizing vitamin E status in cystic fibrosis (CF patients long-term, 29 patients (aged 0.7-29.8 y) were randomly assigned to receive 400 IU of either RRR-alpha-tocopherol (A: 268 mg, n = 10) or all rac-alpha-tocopheryl acetate as a fat-soluble (B: 400 mg, n = 10) or water-miscible preparation (C: 400 mg, n = 9) and were followed for 6 wk. In the whole study group, plasma alpha-tocopherol concentrations increased from baseline (10.5 +/- 4.6 micromol/L) to 3 wk (25.7 +/- 6.5 micromol/L; P < 0.001), but not further between 3 and 6 wk; concentrations at 3 and 6 wk did not differ from those of age-matched control subjects (23.6 +/- 3.9 micromol/L). There was no significant difference in the increase from baseline to 6 wk among preparations A (17.75 +/- 8.43 micromol/L), B (14.0 +/- 9.4 micromol/L), and C (15.5 +/- 7.1 micromol/L). Because of differences in body weight, the dose administered ranged from 5.5 to 47.4 IU x kg-1 x d-1; it correlated positively with the increase in plasma alpha-tocopherol concentrations (P < 0.001). There was no significant difference in the increase in plasma alpha-tocopherol concentrations between patients with CF-associated liver disease (n = 8) who received 10.2 +/- 3.8 IU x kg-1 x d-1 and those without liver disease taking comparable doses. We conclude that CF patients can be efficiently supplemented with 400 IU/d of any one of the three vitamin E preparations and plasma values of healthy control subjects can be achieved. |
| المشرفين على المادة: | 0 (Antioxidants) 1406-18-4 (Vitamin E) 97C5T2UQ7J (Cholesterol) H4N855PNZ1 (alpha-Tocopherol) R0ZB2556P8 (Tocopherols) |
| تواريخ الأحداث: | Date Created: 19960501 Date Completed: 19960606 Latest Revision: 20180330 |
| رمز التحديث: | 20240513 |
| DOI: | 10.1093/ajcn/63.5.722 |
| PMID: | 8615355 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0002-9165 |
|---|---|
| DOI: | 10.1093/ajcn/63.5.722 |